The Journal of Urology 2012-03-01

Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.

Alicia K Morgans, Michael L Hancock, K Gary Barnette, Mitchell S Steiner, Ronald A Morton, Matthew R Smith

Index: J. Urol. 187(3) , 889-93, (2012)

Full Text: HTML

Abstract

Whether race influences bone loss and fracture risk during androgen deprivation therapy for prostate cancer is unknown. Using data from a prospective clinical trial we compared bone mineral density and fracture between African-American and Caucasian men receiving androgen deprivation therapy.A total of 516 subjects were in the placebo group of a 2-year randomized placebo controlled fracture prevention trial, and were African-American (68) or Caucasian (448). We compared baseline characteristics, changes in bone mineral density and rates of new fractures between races.Compared to Caucasian men, African-American men had higher baseline hip bone mineral density (mean ± SD 0.98 ± 0.15 vs 0.91 ± 0.15 gm/m(2), p = 0.001) and similar spine bone mineral density (1.09 ± 0.22 vs 1.11 ± 0.22, p = 0.51). There was no difference in prevalent vertebral fractures between African-American and Caucasian men (7.4% vs 15.0%, p = 0.13). The percentage change in hip bone mineral density at 2 years was similar between African-American and Caucasian men (mean ± SE -2.21% ± 0.59% vs -2.54% ± 0.26%, p = 0.65). Changes in bone mineral density of the lumbar spine were also similar between African-American and Caucasian men (-1.74% ± 0.69% vs -1.30% ± 0.33%, p = 0.64). No new vertebral fractures were reported in African-American men but 2 fractures were reported in Caucasian men.In a clinical trial African-American men receiving androgen deprivation therapy for prostate cancer have a greater hip bone mineral density and tended to have fewer prevalent vertebral fractures than Caucasian men. Despite a lower baseline risk of osteoporosis and fracture, African-American men experience a decrease in bone mineral density similar to that of Caucasian men.Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.


Related Compounds

Related Articles:

Use of SERMs for treatment in postmenopausal women

2014-07-01

[J. Steroid Biochem. Mol. Biol. 142 , 142-54, (2014)]

Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.

2013-12-01

[Biochim. Biophys. Acta 1831(12) , 1657-64, (2013)]

Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.

2013-02-10

[J. Clin. Oncol. 31(5) , 523-9, (2013)]

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

2013-01-01

[J. Urol. 189(1 Suppl) , S45-50, (2013)]

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.

2011-12-01

[J. Urol. 186(6) , 2239-44, (2011)]

More Articles...